7 hours REGN’s Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study Zacks
Regeneron’s phase III study evaluating Eylea HD against stand-of-care Eylea treatment meets the primary endpoint of non-inferior visual gain in RVO patients.
Pharmaceuticals · Regeneron Pharma (REGN)
X